Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Obesity and family practice experts share when it’s safe to prescribe GLP-1 receptor agonists to patients with thyroid ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Merck & Co. Inc. and Hansoh Pharmaceutical Group Co. Ltd. have entered into an exclusive global license agreement for ...